「fortherepublic of kiribati」の検索結果
135件：56～60件目を表示
-
TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; hereinafter: Mochida) and licensed to Senju as...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117_0.pdf -
TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; hereinafter: Mochida) and licensed to Senju as...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf -
千寿製薬株式会社
8月20日 Senju initiated Phase III Clinical Trials in Japan for "SJP-0049" for the treatment of Allergic Conjunctivitis（PDF） 2026年06月01日 Launch of Distribution of 3in1Smart and SPM-700（PDF） 202...
https://www.senju.co.jp/chinese/ -
Overseas Activities | SENJU Pharmaceutical
utical development have no borders. We engage in international activities with a view to the future of pharmaceuticals, transcending national and corporate boundaries. As we enter the era of globaliza...
https://www.senju.co.jp/english/global/ -
Overseas Activities | SENJU Pharmaceutical
utical development have no borders. We engage in international activities with a view to the future of pharmaceuticals, transcending national and corporate boundaries. As we enter the era of globaliza...
http://www.senju.co.jp/english/global/